Search Results Search Sort by RelevanceMost Recent Medicine and Society Mar 2019 How Should Health Care Organizations and Communities Work Together to Improve Neighborhood Conditions? Daniel Skinner, PhD, Berkeley Franz, PhD, and Kelly Kelleher, MD, MPH Partnering with and engaging community members means expressing respect for community members’ on-the-ground experience. AMA J Ethics. 2019;21(3):E281-287. doi: 10.1001/amajethics.2019.281. Policy Forum Apr 2019 How Should Engineered Nanomaterials Be Regulated for Public and Environmental Health? David B. Resnik, JD, PhD Minimizing and managing risks of ENMs means considering whether and when existing legal frameworks offer sufficient protection. AMA J Ethics. 2019;21(4):E363-369. doi: 10.1001/amajethics.2019.363. Health Law Apr 2019 Regulating Nanomedicine at the Food and Drug Administration Jordan Paradise, JD Nanoscale products pose ethical, legal, and policy challenges to governing the use of products that integrate multiple mechanisms of therapeutic action. AMA J Ethics. 2019;21(4):E347-355. doi: 10.1001/amajethics.2019.347. Medicine and Society May 2019 Palliative Care for Patients on Mechanical Circulatory Support Sara E. Wordingham, MD and Colleen K. McIlvennan, DNP, ANP Palliation goals should inform MCS therapy duration, symptom management, and advance care planning and facilitate communication. AMA J Ethics. 2019;21(5):E435-442. doi: 10.1001/amajethics.2019.435. Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care. Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852. Viewpoint Oct 2019 How Moral Case Deliberation Supports Good Clinical Decision Making Giulia Inguaggiato, MPhil, Suzanne Metselaar, PhD, Bert Molewijk, PhD, and Guy Widdershoven, PhD Clarifying both patients’ and professionals’ values fosters good clinical decision making, particularly in situations of uncertainty. AMA J Ethics. 2019;21(10):E913-919. doi: 10.1001/amajethics.2019.913. Case and Commentary Nov 2019 In Experimental Hand Transplantation, Whose Views About Outcomes Should Matter Most? Andrea DiMartini, MD and Mary Amanda Dew, PhD Clinician-researchers deeply invested in data gathering are still obliged to respect a patient-subject’s right to stop being in research. AMA J Ethics. 2019;21(11):E936-942. doi: 10.1001/amajethics.2019.936. Case and Commentary Dec 2019 How Should Physicians Respond When They Learn Patients Are Using Unapproved Gene Editing Interventions? Carolyn Riley Chapman, PhD, MS and Arthur L. Caplan, PhD Responding to patients violating US health commerce regulations can be critical when they buy and use unproven interventions. AMA J Ethics. 2019;21(12):E1021-1028. doi: 10.1001/amajethics.2019.1021. Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036. Pagination First page « First Previous page ‹ Previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page Next › Last page Last »
Medicine and Society Mar 2019 How Should Health Care Organizations and Communities Work Together to Improve Neighborhood Conditions? Daniel Skinner, PhD, Berkeley Franz, PhD, and Kelly Kelleher, MD, MPH Partnering with and engaging community members means expressing respect for community members’ on-the-ground experience. AMA J Ethics. 2019;21(3):E281-287. doi: 10.1001/amajethics.2019.281.
Policy Forum Apr 2019 How Should Engineered Nanomaterials Be Regulated for Public and Environmental Health? David B. Resnik, JD, PhD Minimizing and managing risks of ENMs means considering whether and when existing legal frameworks offer sufficient protection. AMA J Ethics. 2019;21(4):E363-369. doi: 10.1001/amajethics.2019.363.
Health Law Apr 2019 Regulating Nanomedicine at the Food and Drug Administration Jordan Paradise, JD Nanoscale products pose ethical, legal, and policy challenges to governing the use of products that integrate multiple mechanisms of therapeutic action. AMA J Ethics. 2019;21(4):E347-355. doi: 10.1001/amajethics.2019.347.
Medicine and Society May 2019 Palliative Care for Patients on Mechanical Circulatory Support Sara E. Wordingham, MD and Colleen K. McIlvennan, DNP, ANP Palliation goals should inform MCS therapy duration, symptom management, and advance care planning and facilitate communication. AMA J Ethics. 2019;21(5):E435-442. doi: 10.1001/amajethics.2019.435.
Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care.
Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852.
Viewpoint Oct 2019 How Moral Case Deliberation Supports Good Clinical Decision Making Giulia Inguaggiato, MPhil, Suzanne Metselaar, PhD, Bert Molewijk, PhD, and Guy Widdershoven, PhD Clarifying both patients’ and professionals’ values fosters good clinical decision making, particularly in situations of uncertainty. AMA J Ethics. 2019;21(10):E913-919. doi: 10.1001/amajethics.2019.913.
Case and Commentary Nov 2019 In Experimental Hand Transplantation, Whose Views About Outcomes Should Matter Most? Andrea DiMartini, MD and Mary Amanda Dew, PhD Clinician-researchers deeply invested in data gathering are still obliged to respect a patient-subject’s right to stop being in research. AMA J Ethics. 2019;21(11):E936-942. doi: 10.1001/amajethics.2019.936.
Case and Commentary Dec 2019 How Should Physicians Respond When They Learn Patients Are Using Unapproved Gene Editing Interventions? Carolyn Riley Chapman, PhD, MS and Arthur L. Caplan, PhD Responding to patients violating US health commerce regulations can be critical when they buy and use unproven interventions. AMA J Ethics. 2019;21(12):E1021-1028. doi: 10.1001/amajethics.2019.1021.
Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036.